Tech Company Financing Transactions
Neurosterix Funding Round
Neurosterix, operating out of Geneva, received $105 million in funding from RTW Investments, Acorn Bioventures and Affinity Asset Advisors.
Transaction Overview
Company Name
Announced On
11/13/2026
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead clinical-stage program, NTX-253, into Phase 2 clinical development for schizophrenia and support its broader pipeline of selective allosteric modulators.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9 Chemin Des Mines
Geneva, 1202
Switzerland
Geneva, 1202
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators -- molecules that increase or decrease the activity of target receptors by binding outside of the "active site" where endogenous ligands and traditional drugs operate. Through this platform, Neurosterix's novel drug candidates have the potential to provide medicines with improved efficacy, safety and tolerability for patient communities suffering from underserved neurological disorders.
Management Team
Browse more venture capital transactions:
Prev: 11/12/2026: Griffin venture capital transaction
Next: 11/13/2026: feld.energy venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. All VC database entries reported here are derived from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








